For years, lung cancer was thought to be a single illness linked to smoking. But science has taught us that lung cancer is a complex disease with many types and subtypes. It can develop in men and women of different ages and races, regardless of whether they've ever smoked.
One subtype of lung cancer is ALK+ NSCLC. Living with ALK+ NSCLC can be challenging and sometimes discouraging, especially if it continues to grow or spread (progresses). If it does, you should know that there are certain therapies called ALK inhibitors that may help you. Some ALK inhibitors may be effective even after you've already taken one or more prior ALK inhibitors.
Everyone has the ALK gene in each of their cells. If part of the ALK gene breaks off and reattaches the wrong way, it can create an ALK fusion gene. This may cause the cell to multiply out of control, resulting in cancer growth.
Because there are ALK inhibitor treatments available, healthcare providers can create treatment plans specifically for people with ALK+ NSCLC that has spread (metastasized).
NSCLC accounts for 80% to 85% of all lung cancer cases; 3% to 5% of people with NSCLC test positive for the ALK fusion gene and thus have ALK+ NSCLC.
"I remember clearly that day when they called us in to tell us the results of the biomarker testing."
-Jeff, LORBRENA patient
Watch Jeff's story
If you have serious side effects during treatment with LORBRENA, your healthcare provider may change your dose, stop your treatment for a period of time, or completely stop treatment with LORBRENA.
Before taking LORBRENA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. LORBRENA may affect the way other medicines work and other medicines may affect the way LORBRENA works, causing side effects.
Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
Do not take LORBRENA if you take certain other medicines called strong CYP3A inducers. Ask your healthcare provider for a list of these medicines if you are not sure.
The most common side effects of LORBRENA include:
LORBRENA may cause decreased fertility in males. In males, this could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all of the possible side effects of LORBRENA. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
LORBRENA is a prescription medicine that is used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of your body.
Your healthcare provider will perform a test to make sure that LORBRENA is right for you.
It is not known if LORBRENA is safe and effective in children.
Copyright © 2023 Pfizer Inc. All rights reserved.
Patients should always ask their doctors for medical advice about adverse events.
You are encouraged to report an adverse event related to Pfizer products by calling
(US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly.
The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.
The product information provided in this site is intended for residents of the United States. The products discussed herein may have different product labeling in different countries.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.